Study on Sorafenib for Thyroid Cancer
Author Information
Author(s): Marcia S Brose, Christopher M Nutting, Steven I Sherman, Young Kee Shong, Johannes WA Smit, Gerhard Reike, John Chung, Joachim Kalmus, Christian Kappeler, Martin Schlumberger
Primary Institution: The University of Pennsylvania, Royal Marsden Hospital, The University of Texas MD Anderson Cancer Center, Asian Medical Center, Leiden University Medical Center, Bayer Schering Pharma AG, Bayer HealthCare Pharmaceuticals, Institut Gustave Roussy
Hypothesis
Does sorafenib improve progression-free survival in patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer?
Conclusion
The DECISION trial aims to evaluate the efficacy and safety of sorafenib in improving progression-free survival in patients with advanced thyroid cancer.
Supporting Evidence
- Sorafenib has shown median progression-free survival of 58 to 84 weeks in previous studies.
- Partial responses were observed in up to 25% of patients treated with sorafenib.
- Disease control rates ranged from 59% to 100% in phase II trials.
Takeaway
This study is testing a new medicine called sorafenib to see if it helps people with a type of thyroid cancer that doesn't respond to regular treatments.
Methodology
Multicenter, double-blind, randomized, placebo-controlled phase III trial.
Participant Demographics
Patients with locally advanced or metastatic differentiated thyroid cancer, including papillary, follicular, Hürthle cell, and poorly differentiated carcinoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website